$473.90
-1.68%
N/A-$8.10
Salud
Biotecnología
NASDAQ
Negociación activa
Vertex Pharmaceuticals Incorporated es una empresa líder en biotecnología que se centra principalmente en el descubrimiento, el avance y la comercialización de ...
Ejecutivos C-Level
(0)El equipo C-Level forma un liderazgo cohesionado que impulsa la estrategia financiera y la innovación de la empresa.
Miembros clave del equipo
No hay ejecutivos para este nivel
Founder / CEO
1
C-Level
8
VP
0
Board
1
Director / Board
0
Other
0
Key Executives
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
| Reshma Kewalramani FASN | Director Ejecutivo, Presidente y Director | USD 6,141,991 | — | 1973 | Active |
| Charles F. Wagner Jr. | Vicepresidente Ejecutivo, Director de Operaciones y Director Financiero | USD 2,990,992 | 1968 | Active | |
| Mark Bunnage D.Phil | Vicepresidente Ejecutivo y Director Científico | USD 2,387,150 | — | 1969 | Active |
| Carmen Bozic | Vicepresidente Ejecutivo de Desarrollo Global de Medicamentos y Asuntos Médicos y Director Médico | USD 2,270,790 | — | 1963 | Active |
| Ourania Tatsis | Vicepresidente Ejecutivo y Director de Asuntos Regulatorios y Calidad | USD 2,074,398 | — | 1970 | Active |
| Amit K. Sachdev | Vicepresidente Ejecutivo y Director de Asuntos del Paciente y Externos | USD 1,876,721 | 1968 | Active | |
| Jeffrey Marc Leiden | Presidente Ejecutivo | — | — | 1956 | Active |
| Kristen C. Ambrose | Vicepresidente Senior y Director de Contabilidad | — | 1977 | Active | |
| Joy Liu | Vicepresidente Ejecutivo, Director Legal y Secretario Corporativo | — | 1978 | Active | |
| Susie Lisa | Vicepresidente Senior de Relaciones con Inversionistas | — | — | Active |
Executive Compensation
(deduped by latest filing date per person-year)| Filing Date | Year | Name | Position | Level | Salary | Bonus | Stock Award | Option Award | Incentive | Other | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-02 | 2025 | Reshma Kewalramani | CEO CEO and President President | Founder / CEO | $1.60M | $0 | $15.00M | $0 | $4.12M | $423.35K | $21.14M |
| 2026-04-02 | 2025 | Stuart A. Arbuckle | Former Former EVP & Chief Chief Operating Officer | C-Level | $521.49K | $0 | $9.34M | $0 | $0 | $132.93K | $10.00M |
| 2026-04-02 | 2025 | Charles F. Wagner, Jr. EVP & | Chief Chief Operating and Financial Officer | C-Level | $974.81K | $0 | $5.25M | $0 | $1.97M | $51.18K | $8.24M |
| 2026-04-02 | 2025 | Nia Tatsis EVP & | Chief Chief Regulatory and Quality Officer | C-Level | $750.00K | $0 | $4.90M | $0 | $1.28M | $42.23K | $6.97M |
| 2026-04-02 | 2025 | Amit Sachdev EVP & | Chief Chief Patient and External Affairs Officer | C-Level | $700.00K | $0 | $4.90M | $0 | $1.16M | $21.30K | $6.78M |
| 2026-04-02 | 2025 | Carmen Bozic EVP & | Chief Chief Medical Officer | C-Level | $835.00K | $0 | $4.38M | $0 | $1.38M | $57.54K | $6.65M |
| 2026-04-02 | 2024 | Reshma Kewalramani | CEO CEO and President President | Founder / CEO | $1.54M | $0 | $15.00M | $0 | $4.94M | $53.71K | $21.54M |
| 2026-04-02 | 2024 | Stuart A. Arbuckle | Former Former EVP & Chief Chief Operating Officer | C-Level | $941.15K | $0 | $6.23M | $0 | $2.13M | $77.45K | $9.38M |
| 2026-04-02 | 2024 | Charles F. Wagner, Jr. EVP & | Chief Chief Operating and Financial Officer | C-Level | $876.44K | $0 | $5.25M | $0 | $1.82M | $51.52K | $8.00M |
| 2026-04-02 | 2024 | Nia Tatsis EVP & | Chief Chief Regulatory and Quality Officer | C-Level | $691.15K | $0 | $5.25M | $0 | $1.34M | $50.93K | $7.33M |
| 2025-04-03 | 2024 | Stuart A. Arbuckle EVP & | Chief Chief Operating Officer | C-Level | $941.15K | $0 | $6.23M | $0 | $0 | $2.13M | $77.45K |
| 2025-04-03 | 2024 | David M. Altshuler EVP & | Chief Chief Scientific Officer | C-Level | $876.44K | $0 | $5.25M | $0 | $0 | $1.46M | $53.79K |
| 2026-04-02 | 2023 | Reshma Kewalramani | CEO CEO and President President | Founder / CEO | $1.50M | $0 | $15.00M | $0 | $4.05M | $42.55K | $20.59M |
| 2026-04-02 | 2023 | Stuart A. Arbuckle | Former Former EVP & Chief Chief Operating Officer | C-Level | $900.00K | $0 | $6.23M | $0 | $1.82M | $41.74K | $9.00M |
| 2026-04-02 | 2023 | Charles F. Wagner, Jr. EVP & | Chief Chief Operating and Financial Officer | C-Level | $825.00K | $0 | $5.25M | $0 | $1.26M | $40.14K | $7.37M |
| 2024-04-04 | 2023 | Jeffrey M. Leiden Executive Chairman | — | Director / Board | $0 | $0 | $6.50M | $0 | $0 | $95.02K | $6.60M |
| 2025-04-03 | 2023 | Stuart A. Arbuckle EVP & | Chief Chief Operating Officer | C-Level | $900.00K | $0 | $6.23M | $0 | $0 | $1.82M | $41.74K |
| 2025-04-03 | 2023 | David M. Altshuler EVP & | Chief Chief Scientific Officer | C-Level | $825.00K | $0 | $4.38M | $0 | $0 | $1.30M | $41.64K |
| 2024-04-04 | 2022 | Jeffrey M. Leiden Executive Chairman | — | Director / Board | $0 | $0 | $8.50M | $0 | $0 | $92.93K | $8.59M |
| 2023-04-06 | 2022 | David M. Altshuler EVP & Global Research and | Chief Chief Scientific Officer | C-Level | $810.58K | $0 | $4.50M | $0 | $1.17M | $42.14K | $6.53M |
| 2025-04-03 | 2022 | Stuart A. Arbuckle EVP & | Chief Chief Operating Officer | C-Level | $900.00K | $0 | $12.29M | $0 | $0 | $1.76M | $43.10K |
| 2025-04-03 | 2022 | Reshma Kewalramani | CEO CEO and President President | Founder / CEO | $1.40M | $0 | $10.64M | $0 | $0 | $3.78M | $43.06K |
| 2025-04-03 | 2022 | David M. Altshuler EVP & | Chief Chief Scientific Officer | C-Level | $810.58K | $0 | $4.50M | $0 | $0 | $1.17M | $42.14K |
| 2025-04-03 | 2022 | Charles F. Wagner, Jr. EVP & | Chief Chief Financial Officer | C-Level | $793.27K | $0 | $3.75M | $0 | $0 | $1.24M | $28.83K |
| 2024-04-04 | 2021 | Reshma Kewalramani | CEO CEO and President President | Founder / CEO | $1.22M | $0 | $10.92M | $0 | $3.02M | $35.76K | $15.20M |
| 2024-04-04 | 2021 | Jeffrey M. Leiden Executive Chairman | — | Director / Board | $242.31K | $0 | $7.88M | $0 | $0 | $39.67K | $8.16M |
| 2024-04-04 | 2021 | Stuart A. Arbuckle EVP & | Chief Chief Operating Officer | C-Level | $842.31K | $0 | $5.25M | $0 | $1.68M | $40.96K | $7.81M |
| 2022-04-07 | 2021 | Nia Tatsis EVP & | Chief Chief Regulatory and Quality Officer | C-Level | $550.00K | $0 | $5.25M | $0 | $743.82K | $40.03K | $6.58M |
| 2024-04-04 | 2021 | David M. Altshuler EVP & | Chief Chief Scientific Officer | C-Level | $756.73K | $0 | $4.38M | $0 | $1.16M | $39.98K | $6.33M |
| 2023-04-06 | 2021 | David M. Altshuler EVP & Global Research and | Chief Chief Scientific Officer | C-Level | $756.73K | $0 | $4.38M | $0 | $1.16M | $39.98K | $6.33M |
| 2024-04-04 | 2021 | Charles F. Wagner, Jr. EVP & | Chief Chief Financial Officer | C-Level | $729.62K | $0 | $4.38M | $0 | $1.08M | $40.35K | $6.22M |
| 2023-04-06 | 2020 | Jeffrey M. Leiden Executive Chairman | — | Director / Board | $1.12M | $0 | $13.34M | $0 | $1.97M | $43.14K | $16.47M |
| 2021-04-08 | 2020 | Jeffrey M. Leiden Executive Chairman (CEO and | President President through March 31, 2020) | Founder / CEO | $1.12M | $0 | $13.34M | $0 | $1.97M | $43.14K | $16.47M |
| 2023-04-06 | 2020 | Reshma Kewalramani | CEO CEO and President President | Founder / CEO | $1.10M | $0 | $5.25M | $0 | $2.72M | $40.35K | $9.11M |
| 2023-04-06 | 2020 | Stuart A. Arbuckle EVP & | Chief Chief Operating Officer | C-Level | $830.77K | $0 | $5.25M | $0 | $1.16M | $42.60K | $7.28M |
| 2023-04-06 | 2020 | David M. Altshuler EVP & Global Research and | Chief Chief Scientific Officer | C-Level | $752.88K | $0 | $5.25M | $0 | $1.02M | $41.78K | $7.06M |
| 2021-04-08 | 2020 | David Altshuler EVP & Global Research and | Chief Chief Scientific Officer | C-Level | $752.88K | $0 | $5.25M | $0 | $1.02M | $41.78K | $7.06M |
| 2021-04-08 | 2020 | Michael J. Parini (EVP & | Chief Chief Administrative, Legal and Business Development Officer through March 1, 2021) | Other | $830.77K | $0 | $4.38M | $0 | $1.08M | $67.40K | $6.36M |
| 2023-04-06 | 2020 | Charles F. Wagner, Jr. EVP & | Chief Chief Financial Officer | C-Level | $726.92K | $0 | $4.38M | $0 | $946.68K | $41.20K | $6.09M |
| 2022-04-07 | 2019 | Jeffrey M. Leiden Executive Chairman | — | Director / Board | $1.30M | $0 | $9.33M | $4.57M | $3.51M | $73.27K | $18.79M |
| 2021-04-08 | 2019 | Jeffrey M. Leiden Executive Chairman (CEO and | President President through March 31, 2020) | Founder / CEO | $1.30M | $0 | $9.33M | $4.57M | $3.51M | $73.27K | $18.79M |
| 2022-04-07 | 2019 | Stuart A. Arbuckle EVP & | Chief Chief Operating Officer | C-Level | $770.96K | $0 | $3.22M | $1.58M | $1.26M | $37.61K | $6.86M |
| 2022-04-07 | 2019 | Reshma Kewalramani | CEO CEO and President President | Founder / CEO | $702.31K | $0 | $3.22M | $1.58M | $1.26M | $63.66K | $6.82M |
| 2020-04-28 | 2019 | Amit Sachdev EVP & | Chief Chief Patient Officer | C-Level | $540.75K | $0 | $3.22M | $1.58M | $823.29K | $42.05K | $6.20M |
| 2021-04-08 | 2019 | Michael J. Parini (EVP & | Chief Chief Administrative, Legal and Business Development Officer through March 1, 2021) | Other | $785.48K | $0 | $2.68M | $1.31M | $1.22M | $43.61K | $6.04M |
| 2022-04-07 | 2019 | Charles F. Wagner, Jr. EVP & | Chief Chief Financial Officer | C-Level | $492.69K | $140.00K | $1.23M | $600.04K | $992.25K | $36.85K | $3.49M |
| 2020-04-28 | 2019 | Paul M. Silva SVP & Corporate Controller (Interim | CFO CFO for a portion of 2019) | C-Level | $442.57K | $0 | $1.90M | $468.80K | $378.00K | $13.40K | $3.20M |
| 2020-04-28 | 2019 | Ian F. Smith | Former Former EVP & Chief Chief Operating Officer and Former Former Interim Chief Chief Financial Officer | C-Level | $75.19K | $0 | $0 | $0 | $0 | $1.38M | $1.45M |
| 2021-04-08 | 2018 | Jeffrey M. Leiden Executive Chairman (CEO and | President President through March 31, 2020) | Founder / CEO | $1.30M | $0 | $9.80M | $4.24M | $3.44M | $14.73K | $18.80M |
| 2019-04-26 | 2018 | Jeffrey Chodakewitz | Former Former EVP & Chief Chief Medical Officer | C-Level | $618.00K | $0 | $3.15M | $1.36M | $550.64K | $13.78K | $5.70M |
| 2020-04-28 | 2018 | Amit Sachdev EVP & | Chief Chief Patient Officer | C-Level | $540.75K | $0 | $3.15M | $1.36M | $602.26K | $20.67K | $5.68M |
| 2021-04-08 | 2018 | Michael J. Parini (EVP & | Chief Chief Administrative, Legal and Business Development Officer through March 1, 2021) | Other | $746.92K | $0 | $2.63M | $1.14M | $823.38K | $29.00K | $5.37M |
| 2021-04-08 | 2018 | Stuart A. Arbuckle EVP & | Chief Chief Commercial and Operations Officer | C-Level | $721.92K | $0 | $2.63M | $1.14M | $824.17K | $38.97K | $5.35M |
| 2020-04-28 | 2018 | Ian F. Smith | Former Former EVP & Chief Chief Operating Officer and Former Former Interim Chief Chief Financial Officer | C-Level | $850.00K | $0 | $2.63M | $1.14M | $0 | $14.11K | $4.63M |
| 2020-04-28 | 2017 | Jeffrey M. Leiden Executive Chairman (CEO and | President President through March 31, 2020) | Founder / CEO | $1.30M | $0 | $8.75M | $3.70M | $3.46M | $13.11K | $17.23M |
| 2020-04-28 | 2017 | Ian F. Smith | Former Former EVP & Chief Chief Operating Officer and Former Former Interim Chief Chief Financial Officer | C-Level | $848.08K | $0 | $2.63M | $1.11M | $1.34M | $13.11K | $5.94M |
| 2020-04-28 | 2017 | Amit Sachdev EVP & | Chief Chief Patient Officer | C-Level | $540.75K | $0 | $2.63M | $1.11M | $600.23K | $10.00K | $4.89M |
| 2020-04-28 | 2017 | Stuart A. Arbuckle EVP & | Chief Chief Commercial Officer | C-Level | $700.00K | $0 | $2.10M | $888.21K | $699.30K | $13.11K | $4.40M |
| 2019-04-26 | 2016 | Ian F. Smith | Former Former EVP & Chief Chief Operating and Interim Chief Chief Financial Officer | C-Level | $750.00K | $0 | $3.15M | $1.31M | $562.50K | $12.88K | $5.78M |
Total Compensation Trend
Sum of disclosed compensation by year (USD million)
Key Roles Compensation Lines
Top founder/C-level executives over time (USD million)
© Plutux Technology Limited 2026